Chemotherapy waste — also called antineoplastic or cytotoxic waste — is not a single waste stream. It is a set of overlapping regulatory obligations that a hospital pharmacy, oncology unit, or research facility handling antineoplastic agents must satisfy simultaneously: federal RCRA hazardous waste rules for specific P- and U-listed drugs, state-level regulated medical/biomedical waste rules for materials that merely contacted a chemo agent, and the compendial handling standard USP <800> that governs how hazardous drugs are received, stored, prepared, administered, and disposed of in the first place. Treating chemo waste as generic “biohazard” waste, or assuming a red sharps container satisfies the obligation, is one of the most common compliance gaps procurement and EHS staff encounter when a facility adds a new antineoplastic agent to formulary.
This guide is written for hospital pharmacy, oncology, and EHS/procurement staff who need to classify chemo waste correctly, choose the right containers and haulers, and understand where federal RCRA rules stop and state or institutional rules take over. It does not replace your state environmental agency’s guidance or your institution’s biosafety/EHS office — RCRA sets a federal floor, and most states regulate chemotherapy and medical waste more strictly than federal law requires, so confirm specifics against your state hazardous waste and medical waste programs before finalizing a procedure.
Why chemotherapy waste is regulated differently from other lab or clinical waste
Antineoplastic drugs are designed to be cytotoxic — they kill or damage rapidly dividing cells, which is exactly why exposure to workers handling them (compounding, administering, or cleaning up after them) is a recognized occupational hazard, not just a disposal question. That dual concern — worker exposure during handling and environmental fate after disposal — is why chemo waste sits at the intersection of three separate regulatory frameworks rather than one:
- RCRA hazardous waste (40 CFR Parts 261–262, U.S. EPA) — applies only to specific drugs that appear on EPA’s hazardous waste lists, and only above certain thresholds.
- State regulated medical/biomedical waste rules — apply to materials that contacted a chemo drug (gowns, gloves, tubing, IV bags) but don’t meet the RCRA hazardous-waste trigger; these are state, not federal, programs and vary considerably.
- USP <800>, Hazardous Drugs — Handling in Healthcare Settings — a United States Pharmacopeia compounding standard, not a waste-disposal regulation itself, that sets facility, PPE, and workflow requirements (including waste segregation practices) for handling drugs on the NIOSH List of Hazardous Drugs in Healthcare Settings.
A facility can be fully compliant with USP <800> handling practices and still mis-manage the resulting waste under RCRA, or vice versa — the three frameworks have to be satisfied together, not treated as substitutes for one another.
Trace chemotherapy waste vs. bulk (gross) chemotherapy waste
Nearly every chemo waste program is built around this distinction, because it determines which disposal route an item takes:
- Trace chemo waste — items that contacted a chemo drug but retain only residual amounts: empty IV bags and tubing, used syringes (without the needle), gloves, gowns, and prep materials from compounding or administration. The operative concept borrows from RCRA’s “empty container” standard (40 CFR 261.7) — a container is only “RCRA empty” for a listed hazardous waste once residue is removed by practices commonly employed (pouring, pumping, aspirating) and, for most listed wastes, no more than roughly one inch of residue (or a small percentage by weight) remains.
- Bulk (gross) chemo waste — unused or expired full/partial-dose drugs, contents of a spill kit after cleanup, and any container that does not meet the empty-container threshold. Bulk chemo waste involving a listed drug is RCRA hazardous waste, full stop, and must be manifested to a permitted treatment/storage/disposal facility (TSDF).
The complication is the acutely hazardous (“P-listed”) category. Under 40 CFR 261.7(b)(3), containers that held an acutely hazardous waste are only “RCRA empty” after triple rinsing (or an equivalent validated cleaning method) — a far higher bar than the general emptying standard, and one that is rarely practical or safe to perform on a used IV bag or syringe that held a cytotoxic drug. For that reason, many hospital pharmacy and oncology programs — on the recommendation of bodies like the Oncology Nursing Society (ONS) and the American Society of Health-System Pharmacists (ASHP) — choose not to attempt an empty-container determination for P-listed chemo items at all, and instead route all materials that contacted a P-listed drug, trace or not, through their hazardous waste program rather than the regulated medical waste stream. This is a risk-based operational choice, not a uniform federal requirement, so confirm your own facility’s stance against your state hazardous waste agency’s chemo-specific guidance before setting a container policy.
RCRA P-listed and U-listed antineoplastic drugs
Whether a given chemo agent triggers RCRA hazardous waste obligations at all depends on whether it appears on EPA’s hazardous waste lists at 40 CFR 261.33 — RCRA does not treat “chemotherapy drug” as a category; it lists specific chemicals by name. Two listing types show up repeatedly in oncology settings:
- P-listed (acutely hazardous) — the best-known example in oncology is arsenic trioxide (P012), used to treat acute promyelocytic leukemia. P-listed status carries the strictest generator thresholds (see below) and the triple-rinse empty-container standard described above.
- U-listed — commonly encountered U-listed antineoplastic agents include cyclophosphamide (U058), melphalan (U150), mitomycin C (U010), streptozotocin (U206), uracil mustard (U237), chlorambucil (U035), and daunomycin (U059).
This is not an exhaustive list — check 40 CFR 261.33 (or your state’s equivalent hazardous waste list, which may be broader) against every antineoplastic agent your facility stocks, ideally at the point a new drug is added to formulary rather than after waste is already accumulating. Many widely used chemo agents (including several taxanes and monoclonal antibodies) are not RCRA-listed at all, which is precisely why a blanket “all chemo is hazardous waste” policy and a blanket “no chemo is hazardous waste” policy are both wrong — the determination has to be made drug by drug.
Generator status and accumulation limits
Once you’ve identified which drugs your facility’s chemo waste stream contains, RCRA’s generator-status framework applies the same way it does to any other hazardous waste, with one important wrinkle for acutely hazardous drugs. Under 40 CFR Part 262, a facility’s monthly hazardous waste generation rate sets its generator category:
- VSQG (very small quantity generator) — generates ≤100 kg/month, may accumulate ≤1,000 kg on site.
- SQG (small quantity generator) — generates >100 kg but <1,000 kg/month, may accumulate for up to 180 days (270 if hauling more than 200 miles to a TSDF).
- LQG (large quantity generator) — generates ≥1,000 kg/month or more than 1 kg/month of acutely hazardous (P-listed) waste, and is limited to a 90-day accumulation period.
That 1 kg/month P-listed threshold is easy to cross without noticing, since it is measured against the whole waste stream — container, residue, and all — not just the active drug content. A facility generating arsenic trioxide-contaminated waste should track it separately and specifically, rather than assuming its overall hazardous waste tonnage is what determines status.
Facilities generating small volumes at or near the point of use can accumulate hazardous chemo waste in a satellite accumulation area (40 CFR 262.15) without starting the facility’s accumulation clock, subject to the same volume caps and labeling rules that apply to any other RCRA satellite area — see our guide to satellite accumulation area rules for the mechanics.
EPA’s Hazardous Waste Pharmaceuticals Rule (Subpart P)
Healthcare facilities — including hospitals and their pharmacies — that manage hazardous waste pharmaceuticals are also subject to EPA’s Management Standards for Hazardous Waste Pharmaceuticals, codified at 40 CFR Part 266 Subpart P. For facilities that opt into (or are required into) Subpart P, it functions as an alternative, healthcare-specific set of management standards in place of the general Part 262 generator rules for the pharmaceutical waste it covers, and it includes a specific, unconditional prohibition on sewering (flushing or drain-disposing) any hazardous waste pharmaceutical, chemo drugs included. Subpart P’s adoption date and exact scope vary by state — states with their own authorized hazardous waste programs may implement it on a different timeline or with additional requirements — so confirm applicability and any state-specific overlay with your state hazardous waste program rather than assuming the federal baseline is the whole picture.
Subpart P governs the pharmaceutical waste management process; it does not change which specific chemo drugs are P- or U-listed in the first place — that determination still runs through 40 CFR 261.33.
USP <800> and how it interacts with waste disposal
USP General Chapter <800>, Hazardous Drugs — Handling in Healthcare Settings, sets requirements for how facilities receive, store, compound, dispense, administer, and dispose of drugs identified on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. It is a compounding and occupational-safety standard, not a waste-classification regulation — it does not itself decide whether a given item is RCRA hazardous waste — but its requirements for supplemental engineering controls (closed-system transfer devices), PPE, and designated waste containers at the point of use are what most chemo waste segregation programs are actually built around operationally. Facilities that compound or administer sterile hazardous drugs are expected to have a USP <800>-compliant program regardless of whether the specific drug happens to also be RCRA-listed, because the occupational exposure risk exists independent of the waste-disposal classification.
Containers, segregation, and labeling
Practical segregation at the point of use typically separates chemo waste into distinct, clearly labeled container types — the specific color and labeling scheme is set by your state medical waste program and/or institutional policy, not by a single federal standard, so verify the convention your facility and hauler actually use rather than assuming a color universally means the same thing:
- Trace chemo waste containers, physically and visually distinct from general regulated medical waste and from sharps containers, positioned at the point of drug preparation and administration.
- Dedicated chemo sharps containers for needles, syringes, and other sharps that contacted an antineoplastic drug — kept separate from general sharps waste, which typically follows a different disposal path.
- RCRA hazardous waste satellite accumulation containers for bulk/gross chemo waste and any P-listed item your program doesn’t treat as trace-eligible, labeled per 40 CFR 262.15 requirements (accumulation start date once volume limits are exceeded, hazardous waste markings) and physically segregated from the medical-waste stream entirely.
PPE selected for compounding, administering, and cleaning up chemo waste needs to match the chemical resistance profile of the specific agents in use — see our guide to PPE selection for chemical handling for the general selection framework, which applies equally to chemo-specific glove and gown selection guided by USP <800> and NIOSH recommendations.
Disposal routes
In practice, most chemo waste programs end up with two disposal pathways running in parallel:
- Bulk/gross RCRA hazardous chemo waste (and, in many programs, all P-listed-contaminated trace waste as well — see above) is picked up by a licensed hazardous waste transporter and tracked to a permitted TSDF using the Uniform Hazardous Waste Manifest (now filed electronically through EPA’s e-Manifest system for most generators). This is the same manifested, cradle-to-grave tracking chain any other RCRA hazardous waste follows — see our general lab waste disposal guide for how that fits alongside a facility’s other RCRA streams.
- Trace chemo waste that a program has determined is eligible for the medical waste stream (rather than being routed as hazardous waste per the P-listed caution above) typically goes to a permitted medical waste facility for incineration or other approved treatment, under the state’s regulated medical/biomedical waste rules rather than RCRA.
Never dispose of chemo waste, trace or bulk, in general trash, the sanitary sewer, or an autoclave intended for biohazardous (not chemically hazardous) waste — autoclaving does not destroy most cytotoxic chemical hazards, and sewering hazardous waste pharmaceuticals is specifically prohibited under EPA’s Subpart P rule described above regardless of concentration.
A procurement/EHS checklist for onboarding a new antineoplastic agent
- Check the drug against 40 CFR 261.33 (and your state’s hazardous waste list, which may include drugs the federal list does not) before it reaches the floor.
- Confirm whether the drug is also on the current NIOSH List of Hazardous Drugs, which drives USP <800> handling requirements independent of its RCRA status.
- If P- or U-listed, determine (with your EHS/hazardous waste program) whether your facility will attempt an empty-container/trace determination for that drug or route all contaminated materials as hazardous waste by default.
- Confirm your hazardous waste hauler and TSDF contract covers the specific waste codes involved, and that container labeling and satellite accumulation limits are set before the first dose is administered.
- Verify staff handling the drug are trained on the container segregation scheme in use at the point of care, not just general hazardous-waste training.
Frequently asked questions
Is all chemotherapy waste automatically RCRA hazardous waste?
No. RCRA hazardous waste status attaches to specific listed chemicals under 40 CFR 261.33, not to “chemotherapy drugs” as a category. Many commonly used antineoplastic agents are not RCRA-listed at all, while others (like arsenic trioxide) are acutely hazardous. Materials that contacted a non-listed chemo drug are typically managed under state regulated medical waste rules instead.
What’s the difference between trace and bulk chemotherapy waste?
Trace chemo waste is material that contacted a chemo drug but retains only residual amounts (empty IV bags, used gloves and gowns); bulk (gross) chemo waste is unused/expired drug product, spill cleanup material, or anything that doesn’t meet the applicable empty-container threshold. For acutely hazardous (P-listed) drugs, the empty-container bar (triple rinse or equivalent) is high enough that many programs treat all contaminated materials as hazardous waste rather than attempting a trace determination.
Can chemotherapy waste go down the drain?
No. EPA’s Hazardous Waste Pharmaceuticals Rule (40 CFR Part 266 Subpart P) prohibits sewering any hazardous waste pharmaceutical, and sewering non-listed cytotoxic drugs raises independent environmental and wastewater-treatment concerns even where it isn’t a RCRA violation specifically.
Do I need a hazardous waste manifest for chemotherapy waste?
If the waste contains a P- or U-listed drug above your applicable accumulation thresholds, yes — it follows the same Uniform Hazardous Waste Manifest (now largely electronic via EPA’s e-Manifest) and licensed-transporter-to-permitted-TSDF chain as any other RCRA hazardous waste. Trace waste routed through the medical waste stream instead typically follows that state program’s own tracking requirements, which are usually less stringent than a RCRA manifest.
Does USP <800> apply to my facility if we don’t compound chemo drugs on site?
USP <800> applies to any entity that receives, stores, prepares, administers, or disposes of a NIOSH-listed hazardous drug — not just compounding pharmacies. An oncology infusion unit that only administers pre-compounded doses is still within scope for the handling, PPE, and waste-segregation portions of the standard.
This guide covers general federal frameworks and common industry practice; it is not legal or regulatory advice. State hazardous waste and medical waste programs frequently impose additional or stricter requirements than federal RCRA and USP <800> alone — confirm your program’s specific obligations with your state environmental agency, state board of pharmacy, and institutional EHS office before finalizing a chemo waste procedure.
